said Wednesday that fourth-quarter revenue grew to $951.4 million from $926.9 million in the year-ago period.
The biotechnology company reported earnings of 19 cents a share, including charges totaling 5 cents a share. Analysts were expecting the company to earn 25 cents for the quarter, a penny lower than the 26 cents Amgen posted in the same period last year. Representatives from Amgen couldn't be immediately reached for further comment.
, one of the company's top drugs, increased 9% to $533 million, while sales of
dropped 12% to $353 million.
As for 2001, Amgen "continues to expect sales of Epogen and Aranesp combined to grow at a high-teens to low-twenties rate over Epogen alone in 2000." The company added that Neupogen "is expected to grow at a high-single digit rate. Total product sales are expected to grow in the mid- to high-teens. Amgen continues to expect earnings per share to grow at a mid-teens rate in 2001, excluding non-recurring items."